Regulatory Request NIS in Korea
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 658
- Registration Number
- NCT03642717
- Locations
- 🇰🇷
Chonnam National University Hospital, Gwangju, Korea, Republic of
🇰🇷Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇰🇷Korea University Ansan Hospital, Ansan, Korea, Republic of
This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is
- Conditions
- Psoriasis
- Interventions
- Drug: BI 50 mg (fasted)Drug: BI 100 mg (fasted)Drug: BI 200 mg (fasted)Drug: Placebo (fed)Drug: BI 400 mg once daily (fed)Drug: BI 200 mg twice daily, 400 mg total (fed)Drug: Placebo (fasted)Drug: BI 25 mg (fasted)
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 274
- Registration Number
- NCT03635099
- Locations
- 🇺🇸
Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT03629054
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body
- Conditions
- Healthy
- Interventions
- Drug: T1 - Low dose of BI 655130Drug: T2 - Low dose of BI 655130
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT03617835
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
The OPTI Study in Spain Looks at the History Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Inhaled Steroids.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Inhaled corticosteroid
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 901
- Registration Number
- NCT03611777
- Locations
- 🇪🇸
CS Las Cabezas de San Juan, Las Cabezas, Sevilla, Spain
🇪🇸CS Virgen de la Estrella 2, Coria Del Río, Sevilla, Spain
🇪🇸CS Puebla de Cazalla, Puebla De Cazalla, Sevilla, Spain
A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken Up in the Body and How Well They Are Tolerated
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT03608072
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 37
- Registration Number
- NCT03604445
- Locations
- 🇳🇱
Erasmus MC Kanker Instituut, Rotterdam, Netherlands
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇯🇵National Cancer Center Hospital East, Chiba, Kashiwa, Japan
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
- Conditions
- Chronic Kidney Disease
- Interventions
- Drug: Matching placebo
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6609
- Registration Number
- NCT03594110
- Locations
- 🇲🇾
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇨🇦CHUS Hopital Fleurimont, Sherbrooke, Quebec, Canada
🇨🇦CHU de Quebec-Universite Laval Research Centre, Quebec, Canada
A Study to Test Different Doses of BI 456906 in Patients With Obesity
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 131
- Registration Number
- NCT03591718
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
🇩🇪Profil Mainz GmbH & Co. KG, Mainz, Germany
This Study in Healthy Men Tests How Different Doses of BI 1323495 Are Taken up in the Body and How Well They Are Tolerated.
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 63
- Registration Number
- NCT03588390
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany